Trials / Unknown
UnknownNCT05978739
Evaluating Different Doses of Orelabrutinib in MCL
A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- InnoCare Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma to Evaluate the Efficacy and Safety in Mantle Cell Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orelabrutinib High dose | Orelabrutinib will be administered as 3 tablets once per day |
| DRUG | Orelabrutinib Low dose | Orelabrutinib will be administered as 1 tablet once per day |
Timeline
- Start date
- 2023-08-18
- Primary completion
- 2025-02-25
- Completion
- 2025-05-25
- First posted
- 2023-08-07
- Last updated
- 2023-10-25
Locations
20 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05978739. Inclusion in this directory is not an endorsement.